StreetInsider.com News Articles

Alpha Tau reports 100% response rate in head and neck cancer combo trial

Tue, 21 Jul 2026 08:32:13 -0400

Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) announced clinical study results showing a 100% objective response rate among nine evaluable elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) treated with its Alpha DaRT device in combination with pembrolizumab (Keytruda).

The results were presented at the American Head and Neck Society 12th International Conference on Head and Neck Cancer in Boston, Massachusetts, held July 18-22, 2026.

Among the nine evaluable patients, the combination produced four complete responses and five partial responses. Median overall survival was 18.2 months and median progression-free survival was 5.4 months. For comparison, pembrolizumab

Alpha Tau reports 100% response rate in head and neck cancer combo trial

Tue, 21 Jul 2026 08:32:13 -0400

The results were presented at the American Head and Neck Society 12th International Conference on Head and Neck Cancer in Boston, Massachusetts, held July 18-22, 2026.

Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic

Tue, 21 Jul 2026 08:30:00 -0400

- Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer to report results from a study of Alpha DaRT® in combination with pembrolizumab (Keytruda®) in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) -

- Among all nine evaluable patients, the combination produced a systemic objective response rate (ORR) of 100%, including four complete responses and five partial responses, compared to just 19% ORR from historical benchmarks for pembrolizumab monotherapy in this setting -

- Median overall survival of 18.2

Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic

Tue, 21 Jul 2026 08:30:00 -0400

- Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer to report results from a study of Alpha DaRT® in combination with pembrolizumab (Keytruda®) in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) -

- Among all nine evaluable patients, the combination produced a systemic objective response rate (ORR) of 100%, including four complete responses and five partial responses, compared to just 19% ORR from historical benchmarks for pembrolizumab monotherapy in this setting -

- Median overall survival of 18.2

Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic

Tue, 21 Jul 2026 08:30:00 -0400

- Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer to report results from a study of Alpha DaRT® in combination with pembrolizumab (Keytruda®) in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) -

- Among all nine evaluable patients, the combination produced a systemic objective response rate (ORR) of 100%, including four complete responses and five partial responses, compared to just 19% ORR from historical benchmarks for pembrolizumab monotherapy in this setting -

- Median overall survival of 18.2

Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic

Tue, 21 Jul 2026 08:30:00 -0400

- Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer to report results from a study of Alpha DaRT® in combination with pembrolizumab (Keytruda®) in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) -

- Among all nine evaluable patients, the combination produced a systemic objective response rate (ORR) of 100%, including four complete responses and five partial responses, compared to just 19% ORR from historical benchmarks for pembrolizumab monotherapy in this setting -

- Median overall survival of 18.2

Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic

Tue, 21 Jul 2026 08:30:00 -0400

- Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer to report results from a study of Alpha DaRT® in combination with pembrolizumab (Keytruda®) in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) -

- Among all nine evaluable patients, the combination produced a systemic objective response rate (ORR) of 100%, including four complete responses and five partial responses, compared to just 19% ORR from historical benchmarks for pembrolizumab monotherapy in this setting -

- Median overall survival of 18.2

Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic

Tue, 21 Jul 2026 08:30:00 -0400

- Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer to report results from a study of Alpha DaRT® in combination with pembrolizumab (Keytruda®) in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) -

- Among all nine evaluable patients, the combination produced a systemic objective response rate (ORR) of 100%, including four complete responses and five partial responses, compared to just 19% ORR from historical benchmarks for pembrolizumab monotherapy in this setting -

- Median overall survival of 18.2

Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic

Tue, 21 Jul 2026 08:30:00 -0400

- Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer to report results from a study of Alpha DaRT® in combination with pembrolizumab (Keytruda®) in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) -

- Among all nine evaluable patients, the combination produced a systemic objective response rate (ORR) of 100%, including four complete responses and five partial responses, compared to just 19% ORR from historical benchmarks for pembrolizumab monotherapy in this setting -

- Median overall survival of 18.2

Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic

Tue, 21 Jul 2026 08:30:00 -0400

- Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer to report results from a study of Alpha DaRT® in combination with pembrolizumab (Keytruda®) in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) -

- Among all nine evaluable patients, the combination produced a systemic objective response rate (ORR) of 100%, including four complete responses and five partial responses, compared to just 19% ORR from historical benchmarks for pembrolizumab monotherapy in this setting -

- Median overall survival of 18.2

Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic

Tue, 21 Jul 2026 08:30:00 -0400

- Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer to report results from a study of Alpha DaRT® in combination with pembrolizumab (Keytruda®) in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) -

- Among all nine evaluable patients, the combination produced a systemic objective response rate (ORR) of 100%, including four complete responses and five partial responses, compared to just 19% ORR from historical benchmarks for pembrolizumab monotherapy in this setting -

- Median overall survival of 18.2

Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic

Tue, 21 Jul 2026 08:30:00 -0400

- Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer to report results from a study of Alpha DaRT® in combination with pembrolizumab (Keytruda®) in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) -

- Among all nine evaluable patients, the combination produced a systemic objective response rate (ORR) of 100%, including four complete responses and five partial responses, compared to just 19% ORR from historical benchmarks for pembrolizumab monotherapy in this setting -

- Median overall survival of 18.2

Form 6-K Alpha Tau Medical Ltd. For: Jul 21

Tue, 21 Jul 2026 08:30:00 -0400
si-local-file:///var/storage/secattach/20260721/26792818.html

Form 6-K Alpha Tau Medical Ltd. For: Jul 21

Tue, 21 Jul 2026 08:30:00 -0400
si-local-file:///var/storage/secattach/20260721/26792818.html

H.C. Wainwright Reiterates Buy Rating on Alpha Tau Medical Ltd. (DRTS)

Fri, 17 Jul 2026 07:10:32 -0400

H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $15.00 price target on Alpha Tau Medical Ltd. (NASDAQ: DRTS).
The analyst commented: 'Yesterday, Alpha Tau Medical announced that the first immunocompromised patient with recurrent cutaneous squamous cell carcinoma (cSCC) was successfully treated in the ADMIRE study of Alpha DaRT at the Banner MD Anderson Cancer Center in Gilbert, AZ. The ADMIRE study is designed to evaluate whether Alpha DaRT (delivered locally and directly into the tumor) can offer a meaningful alternative across this historically excluded and particularly vulnerable population. Of note, approximately 17M U.S. adults are living with immunosuppression and

Form 6-K Alpha Tau Medical Ltd. For: Jul 15

Wed, 15 Jul 2026 08:30:00 -0400
si-local-file:///var/storage/secattach/20260715/26771461.html

Form 6-K Alpha Tau Medical Ltd. For: Jul 15

Wed, 15 Jul 2026 08:30:00 -0400
si-local-file:///var/storage/secattach/20260715/26771461.html

Form 4 Alpha Tau Medical Ltd. For: Jul 06 Filed by: Levy Raphi

Tue, 07 Jul 2026 07:49:00 -0400
si-local-file:///var/storage/secattach/20260707/26738599.html

Form 4 Alpha Tau Medical Ltd. For: Jul 06 Filed by: Levy Raphi

Tue, 07 Jul 2026 07:49:00 -0400
si-local-file:///var/storage/secattach/20260707/26738599.html

Form 144 Alpha Tau Medical Ltd. Filed by: Levy Raphi

Mon, 06 Jul 2026 11:56:00 -0400
si-local-file:///var/storage/secattach/20260706/26734302.html

Form 144 Alpha Tau Medical Ltd. Filed by: Levy Raphi

Mon, 06 Jul 2026 11:56:00 -0400
si-local-file:///var/storage/secattach/20260706/26734302.html

Form 4 Alpha Tau Medical Ltd. For: Jul 02 Filed by: Levy Raphi

Mon, 06 Jul 2026 11:37:00 -0400
si-local-file:///var/storage/secattach/20260706/26734229.html

Form 4 Alpha Tau Medical Ltd. For: Jul 02 Filed by: Levy Raphi

Mon, 06 Jul 2026 11:37:00 -0400
si-local-file:///var/storage/secattach/20260706/26734229.html

Form 4 Alpha Tau Medical Ltd. For: Jul 01 Filed by: Levy Raphi

Thu, 02 Jul 2026 11:46:00 -0400
si-local-file:///var/storage/secattach/20260702/26725679.html

Form 4 Alpha Tau Medical Ltd. For: Jul 01 Filed by: Levy Raphi

Thu, 02 Jul 2026 11:46:00 -0400
si-local-file:///var/storage/secattach/20260702/26725679.html